Bipolar Disorder Trial, Recruiting NCT05627492 Sponsor: Centre for Addiction and Mental Health Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT05627492
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already taken part in a specific related study called DB1 (049-2021) or DB3 (009-2021)
  • You must be able to speak and understand English
  • You must be between 14 years old and 26 years and 11 months old
  • You must have a diagnosis of bipolar disorder confirmed through a structured interview, OR have a biological parent or sibling diagnosed with bipolar disorder (type I or II)
  • You must currently be seeing a psychiatrist for ongoing mental health care
  • If you have bipolar disorder type I, you must be taking at least one mood-stabilizing medication (such as an antipsychotic, lithium, or certain anti-seizure medications used for mood)
  • You must be willing and able to give your agreement to take part in the study

Who may not be able to join:

  • You have a serious, life-threatening physical health condition that needs immediate medical treatment
  • You are currently experiencing sexual or physical abuse
  • You currently have a significant problem with substance use (such as drugs other than mild cannabis or alcohol use issues)
  • You have an intellectual disability, moderate to severe autism, or a brain-related condition that would make it difficult to actively take part in the therapy used in this study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Benjamin I Goldstein, MD, PhD, Centre for Addiction and Mental Health

Phone: 416-535-8501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre for Addiction and Mental Health
Registry
ClinicalTrials.gov
Start date
9 November 2022
Est. completion
30 November 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Total number of DBT sessions used during the study interval measured using the Therapy Tracking Form; Number of unscheduled/expedited DBT sessions that are required measured using the Therapy; Frequencies of different factors/circumstances leading to the need for unscheduled/expedited DBT sessions measured using the Therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov